A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites

International Journal of Colorectal Disease

Volumn 30, Issue 9, 2015, Pages 1173-1183

  Zhang, Yan ^a   Ma, Junli ^a   Zhang, Sai ^a   Deng, Ganlu ^a   Wu, Xiaoling ^a   He, Jingxuan ^a   Pei, Haiping ^a   Shen, Hong ^a   Zeng, Shan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Clinical characteristics; Colon cancer; Prognosis; Stage III; Tumor location

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; OXALIPLATIN; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; FOLINIC ACID; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CANCER GRADING; CECAL NEOPLASMS; CHEMISTRY; COLON; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CECAL NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COLON; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDYLATE SYNTHASE;

EID: 84940720402     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-015-2273-z     Document Type: Article

References (57)

1. Bufill JA (1990) Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 113(10):779–788
2. Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101(5):403–408
3. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E et al (2012) Colorectal cancer: a tale of two sides or a continuum? Gut 61(6):794–797
4. Pocard M, Salmon RJ, Muleris M, Remvikos Y, Bara J, Dutrillaux B et al (1995) Two colons—two cancers? Proximal or distal adenocarcinoma: arguments for a different carcinogenesis. Bull Cancer 82(1):10–21
5. Gervaz P, Bucher P, Morel P (2004) Two colons—two cancers: paradigm shift and clinical implications. J Surg Oncol 88(4):261–266
6. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N (2008) Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 15(9):2388–2394
7. Shen H, Huang J, Pei H, Zeng S, Tao Y, Shen L et al (2013) Comparative proteomic study for profiling differentially expressed proteins between Chinese left- and right-sided colon cancers. Cancer Sci 104(1):135–141
8. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA et al (2005) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129(3):837–845
9. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES et al (2008) Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 3(11), e3698
10. Ogino S, Chan AT, Fuchs CS, Giovannucci E (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60(3):397–411
11. Jess P, Hansen IO, Gamborg M, Jess T (2013) A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open 3(5)
12. Kim HS (2013) Site-specific colorectal cancer; how is it different? Korean J Gastroenterol 61(2):63–70
13. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA et al (2005) Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 54(3):374–384
14. Benedix F, Meyer F, Kube R, Kropf S, Kuester D, Lippert H et al (2012) Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract 208(10):592–597
15. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R et al (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61(6):847–854
16. Bhangu A, Kiran RP, Slesser A, Fitzgerald JE, Brown G, Tekkis P (2013) Survival after resection of colorectal cancer based on anatomical segment of involvement. Ann Surg Oncol 20(13):4161–4168
17. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351
18. Kosmider S, Lipton L (2007) Adjuvant therapies for colorectal cancer. World J Gastroenterol 13(28):3799–3805
19. Sharif S, O‘Connell MJ, Yothers G, Lopa S, Wolmark N (2008) FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Investig 26(9):956–963
20. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29(11):1465–1471
21. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1(3):227–235
22. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291–1295
23. Reed E (1998) Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 27(1-3):187–201
24. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9–23
25. Park DJ, Lenz HJ (2006) Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol 6(4):337–344
26. Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K et al (2012) ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 7(4):663–671
27. Han JJ, Baek SK, Lee JJ, Kim GY, Kim SY, Lee SH (2014) Combination of TRAP1 and ERCC1 expression predicts clinical outcomes in metastatic colorectal cancer treated with oxaliplatin/5-fluorouracil. Cancer Res Treat 46(1):55–64
28. Kuwabara K, Kumamoto K, Ishibashi K, Okada N, Ishiguro T, Ohsawa T et al (2011) The relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer. Gan To Kagaku Ryoho 38(12):2224–2227
29. Li P, Fang YJ, Li F, Ou QJ, Chen G, Ma G (2013) ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Br J Cancer 108(6):1238–1244
30. Huang MY, Tsai HL, Lin CH, Huang CW, Ma CJ, Huang CM et al (2013) Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol 108(7):457–464
31. Danenberg PV (1977) Thymidylate synthetase—a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473(2):73–92
32. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A (2000) Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6(12):4797–4802
33. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I et al (2002) Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20(7):1721–1728
34. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM et al (2006) Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70(5):366–377
35. Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T et al (2012) TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy. J Surg Oncol 105(6):529–534
36. Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, et al (2014) Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer
37. Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B et al (2009) Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 48(3):368–376
38. Fluge O, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S et al (2009) Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101(8):1282–1289
39. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991
40. Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA (2009) Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum 52(8):1359–1366
41. Bilimoria KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER et al (2008) Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum 51(2):154–161
42. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H (2010) 17,641 patients: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 53(1):57–64
43. Ishihara S, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K et al (2014) Prognostic impact of tumor location in stage IV colon cancer: a propensity score analysis in a multicenter study. Int J Surg 12(9):925–930
44. Roncucci L, Fante R, Losi L, Di Gregorio C, Micheli A, Benatti P et al (1996) Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer 32A(2):295–302
45. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S et al (2003) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9(11):4116–4124
46. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC et al (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12(12):2640–2647
47. Li S, Zhu L, Yao L, Xia L, Pan L (2014) Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy. BMC Gastroenterol 14:154
48. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75(6):903–909
49. Berglund A, Edler D, Molin D, Nordlinder H, Graf W, Glimelius B (2002) Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res 22(6B):3653–3659
50. Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H et al (2008) Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol 23(3):418–423
51. Azzoni C, Bottarelli L, Campanini N, Di Cola G, Bader G, Mazzeo A et al (2007) Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Color Dis 22(2):115–126
52. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ et al (2003) Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12(8):755–762
53. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH et al (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20):4623–4632
54. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L et al (2012) BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 36(5):744–752
55. Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E et al (2012) BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 55(2):128–133
56. Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano S, Hatakeyama K (2004) Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 35(10):1189–1195
57. Kucherlapati MH, Yang K, Fan K, Kuraguchi M, Sonkin D, Rosulek A et al (2008) Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. Proc Natl Acad Sci U S A 105(40):15493–15498